secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-07-20T11:12:37+00:00
Accession:  0001104659-26-084860
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharmaceuticals promotes David House to CFO, effective July 17, 2026
---------------------------------------------------------------------------

- David House appointed CFO; previously SVP Finance and principal financial officer since Aug 2024.
- Base salary $371,315; target bonus 50% of base; annual equity award target $300,000.
- Severance: 12 months base salary on involuntary termination without cause or for good reason.
- Change-in-control acceleration: full vesting of time-based equity if termination within 1 month before or 12 months after CIC.
- Also amended Pierre Kyme's employment agreement to conform change-in-control definition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/0001104659-26-084860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/tm2620782d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer